Archive for 2011

Drug Patent Expirations in November 2011

Drug Patent Expirations in November 2011 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration APHTHASOL Uluru amlexanox 5,362,737 Nov 8, 2011 MAGNEVIST Bayer Hlthcare gadopentetate dimeglumine 5,362,475 Nov 8, 2011 ABLAVAR Lantheus Medcl gadofosveset trisodium 5,362,475 Nov 8, 2011 OMNISCAN Ge Healthcare gadodiamide 5,362,475 Nov 8, 2011 SYMBICORT […]


Click here for reuse options!
Copyright 2011 Biotechblog

Journal of Commercial Biotechnology: New issue now available

The November 2011 issue of the Journal of Commercial Biotechnology is now available.


Click here for reuse options!
Copyright 2011 Biotechblog

FDA at BIO 2011 – Weighing a hefty mission: Where is the balance?

The mission of the Food and Drug Administration (FDA) is to promote public health by ensuring the safety and quality of food and medical products sold in the United States. At this year’s annual Biotechnology Industry Organization (BIO) convention, sig…


Click here for reuse options!
Copyright 2011 Biotechblog

Patent strategies for life sciences companies to navigate the changing patent landscape

As a result of the global recession that began in 2008, life sciences companies face a groundswell of new business and regulatory pressures that includes health care and patent reform, increased pricing pressures, and diluted markets. Bringing new prod…


Click here for reuse options!
Copyright 2011 Biotechblog

Academic entrepreneurship, entrepreneurial universities and biotechnology

There are various definitions of an entrepreneurial university, yet there is a lack of agreement about its core components. This article defines the five key characteristics of an entrepreneurial university based on examples of successful bio-clusters …


Click here for reuse options!
Copyright 2011 Biotechblog

Catalyzing capital for Canada's life sciences industry

Canada’s biotech sector ranks within the top five globally, but its life sciences venture capital (VC) industry is among the worlds weakest. This makes for an interesting case study in understanding the disconnect between low levels of VC and a healthy…


Click here for reuse options!
Copyright 2011 Biotechblog

Catalyzing capital for Canada’s life sciences industry

Canada’s biotech sector ranks within the top five globally, but its life sciences venture capital (VC) industry is among the worlds weakest. This makes for an interesting case study in understanding the disconnect between low levels of VC and a healthy…


Click here for reuse options!
Copyright 2011 Biotechblog

Some considerations for the implementation of disposable technology and single-use systems in biopharmaceuticals

This article, written from an industry perspective, examines the current trend towards the implementation of single-use disposable technologies in the biopharmaceutical and biotechnology sectors. Single-use technologies are generally sterile, plastic d…


Click here for reuse options!
Copyright 2011 Biotechblog

The strength of pharmaceutical IPRs vis-à-vis foreign direct investment in clinical research: Preliminary findings

This article examines the effect of the intellectual property (IP) environment in developing countries on the level of foreign direct investment (FDI) and technology transfer occurring in the biopharmaceutical field in these countries. In particular, i…


Click here for reuse options!
Copyright 2011 Biotechblog

Innovation in R&D: Using design thinking to develop new models of inventiveness, productivity and collaboration

By adapting insights and methodologies from design thinking, a modern scientific R&D organization may have the potential to increase the speed, inventiveness and vitality of their output and become an explosive engine of growth. Modern design consu…


Click here for reuse options!
Copyright 2011 Biotechblog

%d bloggers like this: